|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Ethicon, Inc. |
|---|---|
| Information provided by: | Ethicon, Inc. |
| ClinicalTrials.gov Identifier: | NCT00518102 |
Purpose
The purpose of this retrospective study is to compare the risk of cancers in people who have used becaplermin to that of people with similar characteristics and health issues who have not used becaplermin
| Study Type: | Observational |
| Study Design: | Natural History, Longitudinal, Defined Population, Retrospective Study |
| Official Title: | A Cohort Study of the RIsk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators |
| Estimated Enrollment: | 2000 |
| Study Start Date: | January 1998 |
This is an observational (review of records), retrospective (research activity that is performed after the events under the study have occurred) study where data was collected from a medical claims database. The objective of this study was to determine the incidence of cancer among becaplermin users relative to non-users. Adults who were treated with becaplermin between January 1, 2003 and June 30, 2003 were identified in a health insurance claims database. Another group of adults with similar characteristics but who had not been treated with becaplermin were also identified in the database. The medical records of the two groups were followed for an average of 20 months and any diagnosis of cancer was identified and categorized based on type and location of the cancer. Any incidenceof death from cancer was also identified.
This retrospective study did not involve the use of any investigational drug and did not mandate the treatment regimen that the patients received.
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | CR012010 |
| Study First Received: | August 16, 2007 |
| Last Updated: | August 16, 2007 |
| ClinicalTrials.gov Identifier: | NCT00518102 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
neoplasms Regranex cancer foot ulcer |
PDGF-BB diabetic foot ulcer Becaplermin |
|
Foot Ulcer Diabetic Neuropathies Skin Diseases Growth Substances Ulcer Physiological Effects of Drugs Diabetes Mellitus Vascular Diseases Endocrine System Diseases Foot Diseases Pharmacologic Actions |
Diabetic Angiopathies Neoplasms Pathologic Processes Platelet-derived growth factor BB Angiogenesis Inducing Agents Cardiovascular Diseases Angiogenesis Modulating Agents Skin Ulcer Diabetes Complications Diabetic Foot Leg Ulcer |